Search Results - Hellmann, Matthew

PD-1/PD-L1 axis in lung cancer by Santini, Fernando C., Hellmann, Matthew D.

Get full text Get full text Get full text

Acquired Resistance to Immune Checkpoint Inhibitors by Schoenfeld, Adam J., Hellmann, Matthew D.

Get full text Get full text Get full text

Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma by Hellmann, Matthew, Rizvi, Naiyer, Wolchok, Jedd D., Chan, Timothy A.

Get full text Get full text Get full text

CMET-40. THE DEVELOPMENT OF BRAIN METASTASIS IN THE PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AND MELANOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECT... by Chaul-Barbosa, Caroline, Niotis, Kellyann, Hellmann, Matthew, Callahan, Margaret, Daras, Mariza

Get full text Get full text

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research by Choudhury, Noura J., Riely, Gregory J., Sabbatini, Paul J., Hellmann, Matthew D.

Get full text Get full text Get full text

Opportunistic infections in patients treated with immunotherapy for cancer by Kyi, Chrisann, Hellmann, Matthew D, Wolchok, Jedd D, Chapman, Paul B, Postow, Michael A

Get full text Get full text Get full text

Initial Experience With Lung Cancer Resection Following Treatment With T Cell Checkpoint Inhibitor Therapy by Chaft, Jamie E., Hellmann, Matthew D., Velez, Moises J., Travis, William D., Rusch, Valerie W.

Get full text Get full text Get full text

Genetics and immunology: reinvigorated by Snyder, Alexandra, Makarov, Vladimir, Hellmann, Matthew, Rizvi, Naiyer, Merghoub, Taha, Wolchok, Jedd D, Chan, Timothy A

Get full text Get full text Get full text

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers by Luo, Jia, Rizvi, Hira, Egger, Jacklynn V., Preeshagul, Isabel R., Wolchok, Jedd D., Hellmann, Matthew D.

Get full text Get full text Get full text

Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics by Phillips, Gregory S., Freites-Martinez, Azael, Wu, Jennifer, Chan, Donald, Fabbrocini, Gabriella, Hellmann, Matthew D., Lacouture, Mario E.

Get full text Get full text Get full text

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC by Shaverdian, Narek, Offin, Michael, Shepherd, Annemarie F., Hellmann, Matthew D., Gomez, Daniel R., Chaft, Jamie E., Rimner, Andreas

Get full text Get full text Get full text

Multiple Resolution Residually Connected Feature Streams For Automatic Lung Tumor Segmentation From CT Images by Jiang, Jue, Hu, Yu-chi, Liu, Chia-Ju, Halpenny, Darragh, Hellmann, Matthew D., Deasy, Joseph O., Mageras, Gig, Veeraraghavan, Harini

Get full text Get full text Get full text

Acquired resistance to immunotherapy in MMR-D pancreatic cancer by Hu, Zishuo Ian, Hellmann, Matthew D., Wolchok, Jedd D., Vyas, Monika, Shia, Jinru, Stadler, Zsofia K., Diaz, Luis A., O’Reilly, Eileen M.

Get full text Get full text Get full text

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas by Schilsky, Juliana B., Ni, Ai, Ahn, Linda, Datta, Sutirtha, Travis, William D., Kris, Mark G, Chaft, Jamie E, Rekhtman, Natasha, Hellmann, Matthew D.

Get full text Get full text Get full text

Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas by Eng, Juliana, Woo, Kaitlin M., Sima, Camelia S., Plodkowski, Andrew, Hellmann, Matthew D., Chaft, Jamie, Kris, Mark G., Arcila, Maria E., Ladanyi, Marc, Drilon, Alexander

Get full text Get full text Get full text

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade by Nathanson, Tavi, Ahuja, Arun, Rubinsteyn, Alexander, Aksoy, Bulent Arman, Hellmann, Matthew D., Miao, Diana, Van Allen, Eliezer, Merghoub, Taha, Wolchok, Jedd, Snyder, Alexandra, Hammerbacher, Jeff

Get full text Get full text Get full text

Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer by Shaverdian, Narek, Offin, Michael D., Rimner, Andreas, Shepherd, Annemarie F., Wu, Abraham J., Rudin, Charles M., Hellmann, Matthew D., Chaft, Jamie E., Gomez, Daniel R.

Get full text Get full text Get full text

Adaptive neoadjuvant chemotherapy guided by (18)F-FDG-PET in resectable non-small-cell lung cancers: the NEOSCAN trial by Chaft, Jamie E., Dunphy, Mark, Naidoo, Jarushka, Travis, William D., Hellmann, Matthew, Woo, Kaitlin, Downey, Robert, Rusch, Valerie, Ginsberg, Michelle S., Azzoli, Christopher G., Kris, Mark G.

Get full text Get full text Get full text

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer by Hellmann, Matthew D., Gettinger, Scott, Chow, Laura Q. M., Gordon, Michael, Awad, Mark M., Cha, Edward, Gong, Xiaohua, Zhou, Gongfu, Walker, Chris, Leopold, Lance, Heist, Rebecca S.

Get full text Get full text Get full text

Intra- and Inter-Reader Agreement of iRECIST and RECIST 1.1 Criteria for the Assessment of Tumor Response in Patients Receiving Checkpoint Inhibitor Immunotherapy for Lung Cancer by Castellanos, Sandra Huicochea, Pagano, Andrew, Plodkowski, Andrew J, Girshman, Jeffrey, Hellmann, Matthew D, Rizvi, Hira, Flynn, Jessica, Zheng, Junting, Capanu, Marinela, Halpenny, Darragh F, Ginsberg, Michelle S

Get full text Get full text Get full text